Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

This study tests a new oral drug called NRC-2694-A combined with weekly paclitaxel (a standard chemotherapy drug) in patients with head and neck squamous cell carcinoma (HNSCC) — a cancer of the mouth, throat, or voice box — that has come back or spread and stopped responding to immunotherapy. **You may be eligible if...** - You are 18 or older with confirmed HNSCC that cannot be surgically removed and has progressed after immunotherapy (such as pembrolizumab or nivolumab) - You have not previously received taxane-based chemotherapy (e.g., paclitaxel or docetaxel) for your recurrent or metastatic disease - Your overall health and blood counts are adequate **You may NOT be eligible if...** - You have uncontrolled brain metastases - You have significant heart, liver, lung, kidney, or autoimmune conditions - You have nasopharyngeal or salivary gland cancer - You are currently in another clinical trial - You are pregnant, breastfeeding, or HIV/hepatitis positive (with exceptions for controlled disease) Talk to your doctor to see if this trial is right for you.